ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann Sells 316,667 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann sold 316,667 shares of the firm’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total value of $1,820,835.25. Following the completion of the sale, the chief executive officer now owns 7,948,787 shares of the company’s stock, valued at approximately $45,705,525.25. This represents a 3.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Paul Elliot Mann also recently made the following trade(s):

• On Thursday, April 17th, Paul Elliot Mann sold 316,666 shares of ASP Isotopes stock. The shares were sold at an average price of $5.62, for a total transaction of $1,779,662.92.

ASP Isotopes Price Performance

ASPI stock opened at $5.84 on Friday. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. ASP Isotopes Inc. has a 12 month low of $1.86 and a 12 month high of $9.33. The stock has a market cap of $420.88 million, a PE ratio of -9.57 and a beta of 3.44. The company has a 50-day moving average price of $4.74 and a 200 day moving average price of $5.15.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of ASP Isotopes by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of ASP Isotopes by 56.3% during the fourth quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock worth $46,000 after purchasing an additional 3,682 shares during the last quarter. Rhumbline Advisers lifted its position in shares of ASP Isotopes by 8.2% during the first quarter. Rhumbline Advisers now owns 65,326 shares of the company’s stock worth $306,000 after purchasing an additional 4,963 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of ASP Isotopes by 31.4% during the third quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock valued at $62,000 after purchasing an additional 5,307 shares during the period. Finally, Hanson & Doremus Investment Management bought a new position in shares of ASP Isotopes in the fourth quarter worth about $27,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.